David D. Chism

7.9k total citations · 1 hit paper
30 papers, 1.7k citations indexed

About

David D. Chism is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, David D. Chism has authored 30 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 11 papers in Molecular Biology and 11 papers in Oncology. Recurrent topics in David D. Chism's work include Bladder and Urothelial Cancer Treatments (8 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Renal cell carcinoma treatment (5 papers). David D. Chism is often cited by papers focused on Bladder and Urothelial Cancer Treatments (8 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Renal cell carcinoma treatment (5 papers). David D. Chism collaborates with scholars based in United States, United Kingdom and Italy. David D. Chism's co-authors include Matthew I. Milowsky, William Y. Kim, Jeffrey S. Damrauer, Gopa Iyer, Sara E. Wobker, Huihui Fan, Jen Jen Yeh, Joel S. Parker, Katherine A. Hoadley and Stephanie A. Shore and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Circulation and Journal of Clinical Oncology.

In The Last Decade

David D. Chism

27 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology

2014 613 citations Jeffrey S. Damrauer, Katherine A. Hoadley et al. Proceedings of the National Academy of Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David D. Chism United States	17	687	681	554	490	232	30	1.7k
Yoichi Kameda Japan	24	453 0.7×	541 0.8×	441 0.8×	741 1.5×	267 1.2×	106	1.7k
Hsuan-Ying Huang Taiwan	30	1.2k 1.7×	429 0.6×	700 1.3×	822 1.7×	434 1.9×	55	2.4k
F Rényi-Vámos Hungary	21	525 0.8×	355 0.5×	629 1.1×	365 0.7×	233 1.0×	87	1.5k
Yingyong Hou China	28	1.1k 1.5×	787 1.2×	1.1k 1.9×	1.0k 2.1×	602 2.6×	233	2.9k
Raphaël Maréchal Belgium	22	497 0.7×	550 0.8×	1.5k 2.6×	403 0.8×	479 2.1×	63	2.3k
Paola Martinelli Italy	20	946 1.4×	328 0.5×	597 1.1×	156 0.3×	316 1.4×	36	1.6k
J. Pablo Arnoletti United States	28	537 0.8×	807 1.2×	1.3k 2.4×	532 1.1×	335 1.4×	66	2.1k
Gregory R. Bean United States	20	699 1.0×	213 0.3×	469 0.8×	267 0.5×	348 1.5×	57	1.6k
Manisha R. Shah United States	15	452 0.7×	201 0.3×	410 0.7×	246 0.5×	168 0.7×	20	1.5k
Brian Lu United States	19	510 0.7×	322 0.5×	943 1.7×	342 0.7×	396 1.7×	56	1.6k

Countries citing papers authored by David D. Chism

Since Specialization

Citations

This map shows the geographic impact of David D. Chism's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David D. Chism with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David D. Chism more than expected).

Fields of papers citing papers by David D. Chism

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David D. Chism. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David D. Chism. The network helps show where David D. Chism may publish in the future.

Co-authorship network of co-authors of David D. Chism

This figure shows the co-authorship network connecting the top 25 collaborators of David D. Chism. A scholar is included among the top collaborators of David D. Chism based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David D. Chism. David D. Chism is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Balogh, Erin P., Laura A. Levit, Joseph M. Unger, et al.. (2025). ASCO State of Cancer Care in America Special Report 2025: Access to Cancer Clinical Trials in the United States. JCO Oncology Practice. 21(12). 1746–1758.

Kirkwood, M. Kelsey, Erin P. Balogh, Melissa Accordino, et al.. (2025). Where Have We Been and Where Are We Going? The State of the Hematology and Medical Oncologist Workforce in America. JCO Oncology Practice. 21(12). 1775–1785.

Cascone, Tina, Nir Peled, Alona Zer, et al.. (2025). Abstract CT251: Phase 3 INTerpath-009 study: Individualized neoantigen therapy V940 (mRNA-4157) plus pembrolizumab for resected stage II-IIIB (N2) NSCLC with incomplete pathological response to neoadjuvant immunochemotherapy. Cancer Research. 85(8_Supplement_2). CT251–CT251.

Petrylak, Daniel P., Bernhard J. Eigl, Saby George, et al.. (2023). Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma. Clinical Cancer Research. 30(1). 63–73. 2 indexed citations

Zhang, Jingsong, David D. Chism, Scott T. Tagawa, et al.. (2019). Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 37(7_suppl). 197–197. 1 indexed citations

Campia, Umberto, Javid J. Moslehi, Laleh Amiri‐Kordestani, et al.. (2019). Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association. Circulation. 139(13). e579–e602. 120 indexed citations

Rose, Tracy L., David D. Chism, Ajjai Alva, et al.. (2018). Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy. British Journal of Cancer. 119(7). 801–807. 28 indexed citations

Choueiri, Toni K., James Larkin, Mototsugu Oya, et al.. (2018). Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. The Lancet Oncology. 19(4). 451–460. 207 indexed citations

Johnson, Douglas B., Sally J. York, Michael N. Neuss, et al.. (2018). Impact of the influenza vaccination on cancer patients undergoing therapy with immune checkpoint inhibitors (ICI).. Journal of Clinical Oncology. 36(15_suppl). 3053–3053. 13 indexed citations

10.

Chism, David D.. (2017). Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy. Journal of the National Comprehensive Cancer Network. 15(10). 1277–1284. 32 indexed citations

11.

Nakajima, Erica C., Paul Leger, Ingrid A. Mayer, et al.. (2017). A Case Report of Severe Type B Lactic Acidosis Following First Dose of Nivolumab in a VHL-Mutated Metastatic Renal Cell Carcinoma. PubMed. 1(1). 83–88. 2 indexed citations

12.

Chism, David D. & W. Kimryn Rathmell. (2016). Rest ASSUREd, much can be learned from adjuvant studies in renal cancer. Nature Reviews Nephrology. 12(6). 317–318. 6 indexed citations

13.

Chism, David D., et al.. (2015). Metachronous Bilateral Testicular Leydig-Like Tumors Leading to the Diagnosis of Congenital Adrenal Hyperplasia (Adrenogenital Syndrome). SHILAP Revista de lepidopterología. 2015. 1–6. 8 indexed citations

14.

Chism, David D., et al.. (2014). Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer. Expert Review of Anticancer Therapy. 14(11). 1369–1378. 26 indexed citations

15.

Damrauer, Jeffrey S., Katherine A. Hoadley, David D. Chism, et al.. (2014). Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proceedings of the National Academy of Sciences. 111(8). 3110–3115. 613 indexed citations breakdown →

16.

Ricciardi, Maria Rosaria, Teresa McQueen, David D. Chism, et al.. (2005). Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. Leukemia. 19(9). 1543–1549. 97 indexed citations

17.

Engel, J., Gunhild Keller, Andrew V. Schally, et al.. (2005). Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone–releasing hormone analogues AN-152 and AN-207. Fertility and Sterility. 83(4). 1125–1133. 22 indexed citations

18.

Konopleva, Marina, Elena Elstner, Teresa McQueen, et al.. (2004). Peroxisome proliferator-activated receptor γ and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. Molecular Cancer Therapeutics. 3(10). 1249–1262. 79 indexed citations

19.

Konopleva, Marina, Elena Elstner, Teresa McQueen, et al.. (2004). Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias.. PubMed. 3(10). 1249–62. 88 indexed citations

20.

Shore, Stephanie A., Richard A. Johnston, Igor N. Schwartzman, David D. Chism, & G. G. Krishna Murthy. (2002). Ozone-induced airway hyperresponsiveness is reduced in immature mice. Journal of Applied Physiology. 92(3). 1019–1028. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact